ARVN

Insider trade Sale by Teel Randy (President and CEO)

10d ago

News Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients

14d ago

News Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?

14d ago

Insider trade Sale by Andrew Saik (Chief Financial Officer)

19d ago

Insider trade Sale by Noah Berkowitz (Chief Medical Officer)

19d ago

Insider trade Sale by David K Loomis (VP, Chief Accounting Officer)

19d ago

Insider trade Sale by Angela M Cacace (Chief Scientific Officer)

19d ago

Insider trade Sale by Randy Teel (President and CEO)

19d ago

News Arvinas anticipates U.S. ARV-102 PSP trial by end of 2026 while maintaining cash runway into second half of 2028

20d ago

News Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

20d ago

News Pfizer, Arvinas ink licensing deal with Rigel for breast cancer therapy

21d ago

News Arvinas GAAP EPS of -$0.90 misses by $0.26, revenue of $15.6M misses by $19.24M

21d ago

News Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy

29d ago

News Pfizer, Arvinas breast cancer therapy approved by the FDA

32d ago

Insider trade Sale by Berkowitz Noah (Chief Medical Officer)

74d ago

Insider trade Purchase by Briggs Morrison

84d ago

Insider trade Sale by John G Houston

91d ago

News Arvinas GAAP EPS of -$1.10 misses by $0.62, revenue of $9.5M misses by $27.76M

98d ago

News Arvinas Q4 2025 Earnings Preview

99d ago

Insider trade Sale by Andrew Saik

103d ago

Insider trade Sale by Berkowitz Noah

103d ago

News Gold's big rally has sparked a bearish stock-market signal that hasn't been seen in over 20 years - Business Insider

124d ago

News Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

153d ago

News Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

153d ago